Preliminary voice and speech analysis following fetal dopamine transplants in 5 individuals with

Baker, Kristin K.; Ramig, Lorraine Olson
June 1997
Journal of Speech, Language & Hearing Research;Jun1997, Vol. 40 Issue 3, p615
Academic Journal
Studies preliminary voice and speech analysis following fetal dopamine transplants in individuals with Parkinson disease. Speech and motor exam measures; Phonatory and articulatory functions; Participant characteristics; Data collection; Measurement reliability; Listener perceptual ratings.


Related Articles

  • Effect of Rate Reduction and Increased Loudness on Acoustic Measures of Anticipatory Coarticulation in Multiple Sclerosis and Parkinson's Disease. Tjaden, Kris; Wilding, Gregory E. // Journal of Speech, Language & Hearing Research;Apr2005, Vol. 48 Issue 2, p261 

    The present study compared patterns of anticipatory coarticulation for utterances produced in habitual, loud, and slow conditions by 17 individuals with multiple sclerosis (MS), 12 individuals with Parkinson's disease (PD), and 15 healthy controls. Coarticulation was inferred from vowel F2...

  • Voice Quality in Parkinson's Disease in the Croatian Language Speakers. Bauer, Vladimir; Alerić, Zorica; Jančić, Ervin; Miholović, Vesna // Collegium Antropologicum;Jun2011 Supplement, Vol. 35, p209 

    Parkinson's disease (PD) is well known to cause voice impairments. The aim of this study is to evaluate subjective and objective changes in voice quality in patients with PD in Croatian language speakers. Twenty one patients (11 male and 10 female) with PD and twenty one age-matched (10 male and...

  • Telediagnosis of Parkinson’s Disease Using Measurements of Dysphonia. Sakar, C. Okan; Kursun, Olcay // Journal of Medical Systems;Aug2010, Vol. 34 Issue 4, p591 

    Parkinson’s disease (PD) is a neurological illness which impairs motor skills, speech, and other functions such as mood, behavior, thinking, and sensation. It causes vocal impairment for approximately 90% of the patients. As the symptoms of PD occur gradually and mostly targeting the...

  • New technology helps Parkinson's patients speak louder.  // Medical Device Daily;10/18/2009, p1 

    The article reports on the development of a new technology which helps patients with Parkinson's disease overcome the tendency to speak too quietly. It presents remarks of professor Jessica Huber on the patients. It relates that 89% of those with Parkinson's have voice-related change and 45%...

  • A preamble on parkinsonism. Koranyi, Erwin K. // Journal of Psychiatry & Neuroscience;Sep99, Vol. 24 Issue 4, p296 

    Focuses on the idiopathic motor illness Parkinsonism in Ottawa, Ontario. Clinical manifestations and pathophysiology of the disease; Parallelism between parkinsonism severity and dopamine level in the cortex; Link between cholinergic neurons damage and dementia; Levodopa with carbidopa as the...

  • Combination of two different dopamine agonists in the management of Parkinson's disease. Stocchi, F.; Berardelli, A.; Vacca, L.; Thomas, A.; De Pandis, M.F.; Modugno, N.; Valente, M.; Ruggieri, S. // Neurological Sciences;Sep2002 Supplement 2, Vol. 23, pS115 

    An alternative approach to the symptomatic treatment of parkinsonian patients with and without motor fluctuations is to use dual dopamine agonists. The aim of this study was to investigate the symptomatic effect of administrating a second dopamine agonist to parkinsonian patients already...

  • Clinical Experience with Cabergoline in Patients with Advanced Parkinson's Disease Treated with Levodopa. Marsden, C.D. // Drugs;Jan1998 Supplement 1, Vol. 55 Issue 1, p17 

    The clinical efficacy of the long-acting dopamine agonist cabergoline as an adjunct to levodopa has been investigated in controlled and uncontrolled studies in >1500 patients with advanced Parkinson's disease and motor complications. Four of these studies (including 2 comparisons with placebo...

  • Pharmacodynamic and Pharmacokinetic Features of Cabergoline: Rationale for Use in Parkinson's Disease. Fariello, R.G. // Drugs;Jan1998 Supplement 1, Vol. 55 Issue 1, p10 

    The appearance of late motor complications is the major drawback of long term levodopa therapy in patients with Parkinson's disease. Although disease progression may be a factor in the aetiology of these complications, unfavourable properties of levodopa may promote their development. These...

  • The Significance of Continuous Dopaminergic Stimulation in the Treatment of Parkinson's Disease. Chase, T.N. // Drugs;Jan1998 Supplement 1, Vol. 55 Issue 1, p1 

    Levodopa continues to be the most effective agent for the symptomatic treatment of Parkinson's disease. No other drug matches its ability to suppress parkinsonian symptoms, especially in patients with advanced disease. But over time, initial benefits begin to wane, not so much because of a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics